Save
Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies
Author(s): ,
S.L. Hauser
Affiliations:
University of California, San Francisco, CA, United States
,
G.C. Comi
Affiliations:
University Vita-Salute San Raffaele, Milan, Italy
,
H.-P. Hartung
Affiliations:
Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
,
K. Selmaj
Affiliations:
Medical University of Lodz, Lodz, Poland
,
A. Traboulsee
Affiliations:
The University of British Columbia, Vancouver, BC
,
A. Bar-Or
Affiliations:
McGill University
,
D.L. Arnold
Affiliations:
McGill University; NeuroRx Research, Montreal, QC, Canada
,
G. Klingelschmitt
Affiliations:
F. Hoffmann-La Roche Ltd., Basel, Switzerland
,
A. Kakarieka
Affiliations:
F. Hoffmann-La Roche Ltd., Basel, Switzerland
,
F. Lublin
Affiliations:
Icahn School of Medicine at Mount Sinai, New York, NY, United States
,
H. Garren
Affiliations:
F. Hoffmann-La Roche Ltd., Basel, Switzerland
,
L. Kappos
Affiliations:
University Hospital Basel, Basel, Switzerland
on behalf of the OPERA I and II clinical investigators
on behalf of the OPERA I and II clinical investigators
Affiliations:
ECTRIMS Online Library. Hauser S. Oct 9, 2015; 116634
Stephen Hauser
Stephen Hauser
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: 190

Type: Oral

Abstract Category: Immunomodulation / Immunosuppression

Background: B cells are believed to contribute to the pathogenesis of multiple sclerosis (MS). Ocrelizumab (OCR) is a recombinant humanised monoclonal antibody that selectively targets CD20+ B cells.

Objectives:
OPERA I and II are two identical Phase III, multicentre, randomised, double-blind, double-dummy, parallel-group trials aiming to assess the efficacy and safety of OCR compared with interferon (IFN)-β-1a in patients with relapsing forms of MS (RMS; OPERA I/NCT01247324 and OPERA II/NCT01412333).

Methods:
Patients were randomised (1:1) to receive OCR 600 mg via intravenous infusion every 24 weeks or IFN-β-1a 44 µg subcutaneously three times per week throughout a 96-week treatment period. Eligibility criteria included an age of 18-55 years with a diagnosis of RMS (2010 revised McDonald criteria), Expanded Disability Status Scale (EDSS) score of 0-5.5 at screening and ≥ two documented clinical attacks within 2 years prior or one within 1 year prior to screening. The primary endpoint is the annualised protocol-defined relapse rate at 2 years.

Results:
OPERA I and II randomised 821 and 835 patients, respectively. Mean (standard deviation, SD) age at baseline was 37.0 (9.3) years in OPERA I and 37.3 (9.0) years in OPERA II; 66% of patients in both studies were female. Mean (SD) baseline EDSS scores were 2.77 (1.26)/2.75 (1.34); mean (SD) duration since MS symptom onset was 6.48 (6.16)/6.70 (6.11) years; and mean (SD) duration since MS diagnosis was 3.77 (4.72)/4.14 (5.01) years, for OPERA I/II, respectively. Mean (SD) number of relapses in the 1 and 2 years prior to randomisation was 1.32 (0.65)/1.33 (0.71) and 1.77 (0.89)/1.78 (0.94), respectively, in OPERA I/II. The number of patients untreated with any MS medication in the prior 2 years was 595 (72.5%) for OPERA I and 616 (73.8%) for OPERA II. At baseline, 40.3% and 40.2% of patients had gadolinium-enhancing (Gd+) T1 lesions; mean (SD) number of Gd+ T1 lesions was 1.78 (4.69) and 1.87 (4.88); median (min-max) volume of T2 lesions was 5.88 (0.0-83.2) cm3 and 5.65 (0.0-96.0) cm3; and mean (SD) normalised brain volume was 1500.06 (85.86) cm3 and 1502.72 (91.55) cm3 on brain magnetic resonance imaging in OPERA I and II, respectively.

Conclusions: These baseline data indicate that the populations enrolled in the OPERA I and II studies are consistent with an RMS population. The results of the OPERA studies will provide information on the efficacy and safety of OCR compared with IFN-β-1a in patients with RMS.

Disclosure: Research funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Stephen L Hauser has received grant/research support from F. Hoffmann-La Roche Ltd., Symbiotix and Bionure (SAB member).

Giancarlo C Comi has received compensation for consulting services and/or speaking activities from F. Hoffmann-La Roche Ltd., Novartis, Teva, Sanofi, Genzyme, Merck Serono, Biogen, Bayer, Serono Symposia International Foundation, Excemed, Almirall, Chugai and Receptos.

Hans-Peter Hartung has received honoraria for consulting, serving on steering committees and speaking at scientific symposia with approval by the Rector of Heinrich-Heine University from Bayer, Biogen, F. Hoffmann-La Roche Ltd., GeNeuro, Genzyme, Merck Serono, MedImmmune, Novartis, Octapharma, Opexa, Teva and Sanofi Aventis.

Krzysztof Selmaj has received honoraria for advisory boards from Biogen, Novartis, Teva, F. Hoffmann-La Roche Ltd., Merck, Synthon, Receptos, Genzyme.

Anthony Traboulsee has received grant support from F. Hoffmann-La Roche Ltd. and Sanofi Genzyme; is a steering committee member for F. Hoffmann-La Roche Ltd.; and has been a consultant for Biogen, Chugai, EMD Serono, F. Hoffmann-La Roche Ltd., Medimmune, Sanofi Genzyme, Teva Neuroscience.

Amit Bar-Or has received personal compensation for consulting, serving on scientific advisory boards and/or speaking activities from: Bayer, Bayhill Therapeutics, Berlex, Biogen Idec, BioMS, Diogenix, Eli Lilly, F. Hoffmann-La Roche Ltd., Genentech, GSK, Guthy-Jackson/GGF, Merck Serono, Novartis, Ono Pharmacia, Sanofi-Aventis, Teva Neuroscience and Wyeth.

Douglas Arnold reports equity interest in NeuroRx Research, which performed the MRI analysis for the trial, and consultation fees from Acorda, Biogen Idec, Genzyne, F. Hoffmann-La Roche Ltd., Innate Immunotherapeutics, MedImmune, Mitsubishi Pharma, Novartis, Receptos, Sanofi Aventis, and Teva.

Gaelle Klingelschmitt is an employee of F. Hoffmann-La Roche Ltd.

Algirdas Kakarieka is an employee of F. Hoffmann-La Roche Ltd.

Fred Lublin reports funding of research from Biogen Idec, Novartis Pharmaceuticals Corp, Teva Neuroscience, Inc., Genzyme, Sanofi, Celgene, Transparency Life Sciences, NIH, NMSS; consulting agreements/advisory boards/DSMB for Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc., Novartis,Teva Neuroscience, Actelion, Sanofi, Acorda, Questcor/Malinckrodt, F. Hoffmann-La Roche Ltd., Genentech, Celgene, Genzyme, MedImmune, Osmotica, Xenoport, Receptos, Forward Pharma, BBB technologies, Akros; is co-Chief Editor for Multiple Sclerosis and Related Diseases; and has current financial interests/stock ownership in Cognition Pharmaceuticals, Inc.

Hideki Garren is an employee of F. Hoffmann-La Roche Ltd.

Ludwig Kappos's institution (University Hospital Basel) has received in the last 3 years and used exclusively for research support: steering committee, advisory board, and consultancy fees (Actelion, Addex, Bayer HealthCare, Biogen Idec, Biotica, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi, Santhera, Siemens, Teva, UCB, Xenoport); speaker fees (Bayer HealthCare, Biogen Idec, Merck, Novartis, Sanofi, Teva); support of educational activities (Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi, Teva); royalties (Neurostatus Systems GmbH); grants (Bayer HealthCare, Biogen Idec, European Union, Merck, Novartis, Roche Research Foundation, Swiss MS Society, Swiss National Research Foundation).

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings